PODNL1: A Potential Drug Target and Biomarker for Podocan-like Protein 1

Target Name: PODNL1

NCBI ID: G79883

PODNL1

PODNL1: A Potential Drug Target and Biomarker for Podocan-like Protein 1

Introduction

Podocan-like protein 1 (PODNL1) is a protein that has been identified in various organisms as a key regulator of cell growth, differentiation, and survival. PODNL1 plays a crucial role in the regulation of cell proliferation and has been implicated in the development and progression of various diseases, including cancer. As a result, PODNL1 has emerged as a promising drug target and biomarker. In this article, we will provide an overview of PODNL1, its functions, and potential as a drug target and biomarker.

PODNL1: A Protein Regulator of Cell Growth and Differentiation

Podocan-like protein 1 was first identified in Drosa melanostoma cDNA libraries as a cDNA that encodes a protein with 118 amino acid residues. The protein had a molecular weight of 13.9 kDa and a calculated pI of 6.5. PODNL1 is a member of the podocan family , which includes several similar proteins that are involved in the regulation of cell growth and differentiation. The podocan family proteins have been implicated in the development and progression of various diseases, including cancer.

PODNL1 Functions as a Negative Regulator of the Growth Factor Signaling Pathway

Several studies have shown that PODNL1 functions as a negative regulator of the growth factor signaling pathway. PODNL1 has been shown to inhibit the activity of the protein tyrosine kinase (TK), which is a key enzyme involved in the regulation of cell growth and differentiation. In addition, PODNL1 has been shown to interact with the protein negative regulator of the TK signaling pathway, p16INK4a. This interaction between PODNL1 and p16INK4a suggests that PODNL1 may play a role in the regulation of TK signaling pathway.

PODNL1 as a Potential Drug Target

The potential of PODNL1 as a drug target is based on its functions as a negative regulator of the growth factor signaling pathway and its involvement in the regulation of cell growth and differentiation. PODNL1 has been shown to interact with several protein substrates, including the protein PDGFR -尾, which is a key receptor for the tyrosine kinase tyrosine-protein kinase (TK). This interaction suggests that PODNL1 may be a potential target for small molecules that can inhibit the activity of TK and PDGFR-尾.

PODNL1 as a Biomarker

PODNL1 has also been shown to be expressed in various tissues and organs, including human tissues. This suggests that PODNL1 may be a potential biomarker for the diagnosis and monitoring of diseases associated with podocan-like protein 1. In addition, the regulation of PODNL1 has has been shown to be involved in the development and progression of various diseases, including cancer. This suggests that PODNL1 may be a potential biomarker for the diagnosis and monitoring of cancer.

Conclusion

Podocan-like protein 1 (PODNL1) has been identified as a protein that plays a crucial role in the regulation of cell growth and differentiation. PODNL1 has been shown to function as a negative regulator of the growth factor signaling pathway and its involvement in the regulation of cell growth and differentiation makes it a potential drug target. In addition, PODNL1 has been shown to be expressed in various tissues and organs, which makes it a potential biomarker for the diagnosis and monitoring of diseases associated with podocan-like protein 1. Further research is needed to fully understand the functions

Protein Name: Podocan Like 1

The "PODNL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PODNL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets